Literature DB >> 15073807

Regulatory pharmacovigilance in the United Kingdom: current principles and practice.

P C Waller1, R A Coulson, S M Wood.   

Abstract

Year:  1996        PMID： 15073807     DOI： 10.1002/(SICI)1099-1557(199611)5:6<363::AID-PDS249>3.0.CO;2-7

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  13 in total

1.  The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.

Authors:  R M Martin; N R Dunn; S Freemantle; S Shakir
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.

Authors:  Panos Tsintis; Edith La Mache
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Reporting adverse drug reactions in HIV infection.

Authors:  P R Arlett; E H Lee; M Hooker; J H Darbyshire; A M Breckenridge
Journal:  Genitourin Med       Date:  1997-10

4.  Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.

Authors:  R M Martin; S Shakir
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Surveillance for fatal suspected adverse drug reactions in the UK.

Authors:  A Clarkson; I Choonara
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

6.  Patient reporting of potential adverse drug reactions: a methodological study.

Authors:  N Jarernsiripornkul; J Krska; P A G Capps; R M E Richards; A Lee
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

7.  Post-marketing studies: the work of the Drug Safety Research Unit.

Authors:  F J Mackay
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

8.  Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.

Authors:  Miranda Davies; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Authors:  Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research.

Authors:  Hun Sung Kim; Hyunah Kim; Yoo Jin Jeong; Tong Min Kim; So Jung Yang; Sun Jung Baik; Seung Hwan Lee; Jae Hyoung Cho; In Young Choi; Kun Ho Yoon
Journal:  Endocrinol Metab (Seoul)       Date:  2017-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.